Wen is among the 40 finalists heading to Washington D.C. Thursday to present their projects to panels of experts. The winners ...

In a report released today, Tyler Van Buren from TD Cowen maintained a Buy rating on Regeneron (REGN – Research Report), with a price target of ...

Regeneron Pharmaceuticals has received a positive opinion from the European Medicines Agency’s human medicines committee for ...

In a small study in a community oncology practice, more than 60% of patients with advanced squamous cell skin cancer treated ...

Merck’s Keytruda holds on to the top spot while AbbVie’s Humira—once the world’s top-selling drug—continues to cede its ...

The "Inclusion Body Myositis - Pipeline Insight, 2025" report has been added to ResearchAndMarkets.com's offering.This report offers in-depth insights into the Inclusion Body Myositis (IBM) pipeline, ...

On February 18, 2025, in United States v. Regeneron Pharmaceuticals, the First Circuit held that to establish civil liability under the False ...

Physicians’ Education Resource (PER®) is excited to announce the launch of Retina Resource, a comprehensive source of cutting ...

While Bayer’s consumer and crop science divisions continued to slide—both in the fourth quarter and in 2024 overall—the ...

On Feb. 18, 2025, the U.S. Court of Appeals for the First Circuit adopted the “but for” causality standard for violations of the federal ...

The Federal Circuit upheld a preliminary injunction blocking the launch of a Celltrion Inc. biosimilar version to Regeneron ...

Intellia Therapeutics (NASDAQ:NTLA – Get Free Report) had its price objective dropped by equities researchers at Truist ...